Linoleoyl ethanolamide-d4

• UNSPSC Description:

  Linoleoyl ethanolamide-d4 is a deuterated labeled Linoleoyl ethanolamide[1]. Linoleoyl ethanolamide (Linoleic acid monoethanolamide) is classified as a fatty acid ethanolamide. Linoleoyl ethanolamide only weakly binds G-protein-coupled cannabinoid receptors of type-1（CB1）and CB2 receptors, and inhibits the binding of [3H]CP-55,940 with Kis of 10 and 25 μM, respectively. Linoleoyl ethanolamide is 4-fold less potent than anandamide at causing catalepsy in mice and it does not prolong sleep time[2][3].

• Target Antigen:

  Cannabinoid Receptor; Isotope-Labeled Compounds

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  GPCR/G Protein;Neuronal Signaling;Others

• Field of Research:

  Neurological Disease

• Smiles:

  CCCCC/C=C\C/C=C\CCCCCCCC(NC([2H])([2H])C([2H])([2H])O)=O

• Molecular Weight:

  327.54

• References & Citations:

  [1]Wang X, et al. X. Synthesis of linoleoyl ethanolamide. J Oleo Sci. 2013;62(6):427-433. |[2]Lin S, et al. Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability. J Med Chem. 1998;41(27):5353-5361. |[3]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  1451194-69-6